Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 2

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 2
---
 or the 2024 Registration
Statement, which was declared effective by the SEC on February 16, 2024 and subsequentially amended, which originally covered the resale
from time to time by the selling shareholders identified in the prospectus that forms a part of the 2024 Registration Statement, of up
to 1,126,480 Common Shares, issuable upon the exercise of the January 2024 PIPE Warrants.

In connection with our issuance of convertible
promissory notes, or the Promissory Notes, pursuant to securities purchase agreements entered into on September 17, 2025, or the SPAs,
with certain institutional investors, or the CLA Investors, the number of Common Shares underlying the January 2024 PIPE Warrants was
adjusted in accordance with the terms of the January 2024 PIPE Warrants. As a result of such adjustment, the January 2024 PIPE Warrants
are now exercisable for an additional 5,781,250 Common Shares beyond the 1,126,480 Common Shares registered in the 2024 Registration Statement.
This prospectus is being filed to register the resale of these additional 5,781,250 Common Shares issuable upon exercise of the January
2024 PIPE Warrants, as a result of the adjustment.

The selling shareholders are identified in
the table commencing on page 14. We will not receive any proceeds from the sale of the common shares by the selling shareholders. All
net proceeds from the sale of the common shares covered by this prospectus will go to the selling shareholders. However, we may receive
the proceeds from any exercise of warrants if the selling shareholders do not exercise the warrants on a cashless basis, if and when exercised.
See “Use of Proceeds.”

The selling shareholders may sell all or a
portion of the common shares from time to time in market transactions through any market on which our common shares are then traded, in
negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated
prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale. We will
bear all of the expenses incurred in connection with the registration of these shares. The selling shareholders will pay any underwriting
discounts and selling commissions and/or similar charges incurred in connection with the sale of the shares. See “Plan of Distribution”.

Our Common Shares are currently traded on the Nasdaq